BofA lowered the firm’s price target on Dentsply Sirona (XRAY) to $16 from $19 and keeps a Neutral rating on the shares. The firm is incrementally more cautious on the outlook for dental companies and see risks to EPS guidance for the group, driven by both tariff risk and weakening consumer sentiment, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona files automatic mixed securities shelf
- Dentsply Sirona appoints David Ferguson as SVP, global business unit leader
- Microsoft, Intel upgraded: Wall Street’s top analyst calls
- Dentsply Sirona price target lowered to $18 from $21 at Mizuho
- Dentsply Sirona downgraded to Hold from Buy at Needham